Back to News
Market Impact: 0.12
Celea Therapeutics Presents SURPASS-IPF Phase 3 Trial Design and Statistical Considerations for Evaluating Clinical Trials in Idiopathic Pulmonary Fibrosis at the IPF Summit 2026
Source: Business Wire
Healthcare & Biotech
Celea Therapeutics presented the Phase 3 SURPASS-IPF trial design and statistical considerations at the IPF Summit. The announcement provides no clinical efficacy, safety, enrollment, timing, or financial data, limiting its immediate market relevance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
More News
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- Why is Toho stock volatile today?
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron
- Some Oura IPO Investors Were Said to Push Back Citing Valuation